Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis
-
Published:2024-01
Issue:1
Volume:105
Page:31-34
-
ISSN:0085-2538
-
Container-title:Kidney International
-
language:en
-
Short-container-title:Kidney International
Author:
Rovin Brad H.ORCID,
Ayoub Isabelle M.ORCID,
Chan Tak Mao,
Liu Zhi-HongORCID,
Mejía-Vilet Juan M.,
Balk Ethan M.ORCID,
Gordon Craig E.,
Adam Gaelen,
Tonelli Marcello A.,
Cheung MichaelORCID,
Earley AmyORCID,
Floege Jürgen
Reference7 articles.
1. KDIGO 2021 clinical practice guideline for the management of glomerular diseases;Kidney Int,2021
2. Two-year, randomized, controlled trial of belimumab in lupus nephritis;Furie;N Engl J Med,2020
3. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial;Rovin;Lancet,2021
4. Tacrolimus protects podocytes from injury in lupus nephritis partly by stabilizing the cytoskeleton and inhibiting podocyte apoptosis;Liao;PLoS One,2015
5. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis;Rovin;Kidney Int,2022